Tokyo, Oct. 15 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000059028) titled 'A Cohort Study on the Association Between Serum Erythropoietin Dynamics and Prognosis in Patients with Metastatic Renal Cell Carcinoma Treated with Belzutifan' on Oct. 15.
Study Type:
Observational
Primary Sponsor:
Institute - Kobe University Graduate School of Medicine
Condition:
Condition - renal cell carcinoma
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - To investigate the association between serum erythropoietin (EPO) dynamics during belzutifan therapy and treatment outcomes (progression-free survival) as well as adverse events (anemia and hypoxia) in patients with metastatic or advanced renal cell carcinoma.
Basic objectives2 - Efficacy
Eligibility:
Age-lower limit - 20
years-old
= 20 years
Written informed consent obtained from the patient
Key exclusion criteria - Patients concurrently receiving anticancer therapy for another malignancy (except hormonal therapy for prostate cancer)
Patients with severe cardiopulmonary disease or uncontrolled infections
Patients deemed inappropriate for study participation by the principal investigator
Target Size - 45
Recruitment Status:
Recruitment status - Preinitiation
Date of protocol fixation - 2025 Year 09 Month 30 Day
Anticipated trial start date - 2025 Year 10 Month 15 Day
Last follow-up date - 2028 Year 03 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000067287
Disclaimer: Curated by HT Syndication.
